Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.81
BIOC's Cash to Debt is ranked higher than
66% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.99 vs. BIOC: 1.81 )
BIOC' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 1.81

Equity to Asset 0.34
BIOC's Equity to Asset is ranked higher than
57% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. BIOC: 0.34 )
BIOC' s 10-Year Equity to Asset Range
Min: -18.63   Max: 0.83
Current: 0.34

-18.63
0.83
Z-Score: -21.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -16055.26
BIOC's Operating margin (%) is ranked lower than
55% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. BIOC: -16055.26 )
BIOC' s 10-Year Operating margin (%) Range
Min: -1227100   Max: -5928.36
Current: -16055.26

-1227100
-5928.36
Net-margin (%) -19022.37
BIOC's Net-margin (%) is ranked lower than
55% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. BIOC: -19022.37 )
BIOC' s 10-Year Net-margin (%) Range
Min: -1362900   Max: -6890.3
Current: -19022.37

-1362900
-6890.3
ROE (%) -1998.48
BIOC's ROE (%) is ranked lower than
55% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. BIOC: -1998.48 )
BIOC' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -1998.48

ROA (%) -195.69
BIOC's ROA (%) is ranked lower than
53% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. BIOC: -195.69 )
BIOC' s 10-Year ROA (%) Range
Min: -694.81   Max: -659.5
Current: -195.69

-694.81
-659.5
ROC (Joel Greenblatt) (%) -3122.31
BIOC's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. BIOC: -3122.31 )
BIOC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3360.96   Max: -1614.63
Current: -3122.31

-3360.96
-1614.63
» BIOC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2012

BIOC Guru Trades in Q2 2012

Jim Simons 483,500 sh (-1.49%)
Chuck Royce 695,891 sh (-12.97%)
» More
Q3 2012

BIOC Guru Trades in Q3 2012

Jim Simons 487,800 sh (+0.89%)
Chuck Royce 680,791 sh (-2.17%)
» More
Q4 2012

BIOC Guru Trades in Q4 2012

Jim Simons 491,500 sh (+0.76%)
Chuck Royce 680,791 sh (unchged)
» More
Q1 2013

BIOC Guru Trades in Q1 2013

Chuck Royce Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BIOC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.23
BIOC's P/B is ranked higher than
77% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.49 vs. BIOC: 3.23 )
BIOC' s 10-Year P/B Range
Min: 2.1   Max: 5.65
Current: 3.23

2.1
5.65
P/S 20.17
BIOC's P/S is ranked higher than
59% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.14 vs. BIOC: 20.17 )
BIOC' s 10-Year P/S Range
Min: 7.88   Max: 35.33
Current: 20.17

7.88
35.33
EV-to-EBIT -0.55
BIOC's EV-to-EBIT is ranked higher than
71% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIOC: -0.55 )
BIOC' s 10-Year EV-to-EBIT Range
Min: -2.4   Max: -0.1
Current: -0.55

-2.4
-0.1
Current Ratio 7.83
BIOC's Current Ratio is ranked higher than
94% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. BIOC: 7.83 )
BIOC' s 10-Year Current Ratio Range
Min: 0.02   Max: 10.2
Current: 7.83

0.02
10.2
Quick Ratio 7.70
BIOC's Quick Ratio is ranked higher than
95% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. BIOC: 7.70 )
BIOC' s 10-Year Quick Ratio Range
Min: 0.02   Max: 10.09
Current: 7.7

0.02
10.09

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.75
BIOC's Price/Net Cash is ranked higher than
95% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIOC: 4.75 )
BIOC' s 10-Year Price/Net Cash Range
Min: 3.84   Max: 5.22
Current: 4.75

3.84
5.22
Price/Net Current Asset Value 4.57
BIOC's Price/Net Current Asset Value is ranked higher than
94% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIOC: 4.57 )
BIOC' s 10-Year Price/Net Current Asset Value Range
Min: 3.82   Max: 5.02
Current: 4.57

3.82
5.02
Price/Tangible Book 3.23
BIOC's Price/Tangible Book is ranked higher than
86% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.53 vs. BIOC: 3.23 )
BIOC' s 10-Year Price/Tangible Book Range
Min: 3.5   Max: 3.88
Current: 3.23

3.5
3.88
Price/Median PS Value 1.09
BIOC's Price/Median PS Value is ranked higher than
79% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. BIOC: 1.09 )
BIOC' s 10-Year Price/Median PS Value Range
Min: 0.71   Max: 1.2
Current: 1.09

0.71
1.2
Earnings Yield (Greenblatt) -181.80
BIOC's Earnings Yield (Greenblatt) is ranked lower than
56% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. BIOC: -181.80 )
BIOC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -181.8

» More Articles for BIOC

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest volume increases Dec 24 2014
Biocept's Patented Platform Identifies Clinically HER2-Negative Patients With HER2-Positive... Dec 17 2014
Biocept's Patented Platform Identifies Clinically HER2-Negative Patients With HER2-Positive... Dec 17 2014
Biocept Expands Worldwide Microchannel Patent Protection to South Korea Dec 15 2014
Biocept Expands Worldwide Microchannel Patent Protection to South Korea Dec 15 2014
Biocept Appoints Experienced Physician as Medical Director Dec 03 2014
Biocept Appoints Experienced Physician as Medical Director Dec 03 2014
BIOCEPT INC Financials Nov 22 2014
BIOCEPT INC Files SEC form 10-Q, Quarterly Report Nov 14 2014
Biocept Reports Third Quarter 2014 Financial Results Nov 13 2014
BIOCEPT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 13 2014
Biocept Reports Third Quarter 2014 Financial Results Nov 13 2014
Biocept Launches Lung Cancer Offering Nov 12 2014
Biocept Launches Lung Cancer Offering Nov 12 2014
Biocept, Inc. Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results Nov 06 2014
Biocept, Inc. Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results Nov 06 2014
Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells Oct 13 2014
Biocept Expands Collaboration With MD Anderson Cancer Center Oct 07 2014
Biocept to Present at the 13th Annual BIO Investor Forum Sep 30 2014
BIOCEPT INC Files SEC form 10-Q, Quarterly Report Aug 08 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK